[Response to OK-432 (picibanil) in cancer patients and change of immunological parameters for the administration of OK-432 (picibanil)].
Kato
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000372:Agglutination Tests; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D012882:Skin Tests; D013291:Streptococcus / Q000276:immunology
D001688:Biological Products; D010844:Picibanil